NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte–predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.

Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics

“…At present, chemotherapy is still the backbone of cancer treatment and doxorubicin is one of the most widely prescribed first-line chemotherapy drugs. As recommended by the National Comprehensive Cancer Network guidelines, doxorubicin is frequently used in various multi-agent chemotherapy regimens for acute lymphoblastic leukemia, Hodgkin lymphoma and invasive breast cancer [5][6][7]. The systemic side effects of doxorubicin have been extensively studied, and there is considerable evidence that female gonads are vulnerable to doxorubicin [8].…”

Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study

“…High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed and refractory (RR) classic Hodgkin Lymphoma (cHL) [ 1 , 2 ]. Unfortunately, disease recurrence remains the major cause of ASCT failure.…”

Liposomal doxorubicin supercharge‐containing front‐line treatment in patients with advanced‐stage diffuse large B‐cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single‐centre phase II study

“…27,39,40 Thus, the early intensification of treatment is controversial and is not recommended in international guidelines. 27,39 Our prospective phase II trial was sufficiently large to provide enough evidence of the efficacy of liposomal doxorubicin supercharge-based front-line therapy in both types of lymphomas in patients at high risk, as reflected by a substantial increase in the number of patients with interim-FDG-PET negativity. In our DLBCL subgroup, the negative interim-FDG-PET scans rate following the three scheduled R-COMP-DI cycles was 85% versus 62% of the pooled summary negativity interim PET rate of the literature following R-CHOP-21 in a similar patient setting.…”

“…38 However, all these approaches are not routinely employed because they have not been clearly proven effective, safe, and economically advantageous. 27,39,40 Thus, the early intensification of treatment is controversial and is not recommended in international guidelines. 27,39 Our prospective phase II trial was sufficiently large to provide enough evidence of the efficacy of liposomal doxorubicin supercharge-based front-line therapy in both types of lymphomas in patients at high risk, as reflected by a substantial increase in the number of patients with interim-FDG-PET negativity.…”

“…However, all these approaches are not routinely employed because they have not been clearly proven effective, safe, and economically advantageous 27,39,40 . Thus, the early intensification of treatment is controversial and is not recommended in international guidelines. 27,39 …”